Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanna R Stevens

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Journal of Cardiac Failure|February 27, 2018
Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical TrialsMichael S Kiernan, Susanna R Stevens, W H Wilson Tang, et al.
Heart (British Cardiac Society)|June 26, 2015
Characterising and predicting bleeding in high-risk patients with an acute coronary syndromeRazi Khan, Renato D Lopes, Megan L Neely, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Diabetes Care|October 16, 2016
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSJan H Cornel, George L Bakris, Susanna R Stevens, et al.
American Heart Journal|June 23, 2014
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAnna Kotsia, Emmanouil S Brilakis, Claes Held, et al.
American Heart Journal|March 31, 2015
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trialJan H Cornel, Renato D Lopes, Stefan James, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Journal of Cardiac Failure|February 27, 2018
Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical TrialsMichael S Kiernan, Susanna R Stevens, W H Wilson Tang, et al.
Heart (British Cardiac Society)|June 26, 2015
Characterising and predicting bleeding in high-risk patients with an acute coronary syndromeRazi Khan, Renato D Lopes, Megan L Neely, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Diabetes Care|October 16, 2016
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSJan H Cornel, George L Bakris, Susanna R Stevens, et al.
American Heart Journal|June 23, 2014
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAnna Kotsia, Emmanouil S Brilakis, Claes Held, et al.
American Heart Journal|March 31, 2015
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trialJan H Cornel, Renato D Lopes, Stefan James, et al.
Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Pageof 11